In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy

Cancer Research

Volumn 60, Issue 5, 2000, Pages 1193-1196

  Rogulski, Kenneth R ^a   Freytag, Svend O ^a   Zhang, Kang ^a   Gilbert, Jeff D ^a   Paielli, Dell L ^a   Kim, Jae Ho ^a   Heise, Carla C ^b   Kirn, David H ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COBALT 60; FLUOROURACIL; PROTEIN P53;

ADENOVIRUS; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER RADIOTHERAPY; DNA REPLICATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS; VIRUS REPLICATION;

ADENOVIRIDAE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MUTATION; NEOADJUVANT THERAPY; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034161976     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
2. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
3. Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., and Kim, J. H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther., 9: 1323-1333, 1998.
4. Yew, P. R., and Burke, A. J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (Lond.), 357: 82-85, 1992.
5. Hollenstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
6. Bergh, J., Norberg, T., Siogren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
7. Goodrum, F., and Ornelles, D. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol., 71: 548-561, 1997.
8. Goodrum, F., and Ornelles, D. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol., 72: 9479-9490, 1998.
9. Rothmann, T., Hengstermann, N., Whitaker, M., Sheffner, M., and Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol., 72: 9470-9478, 1998.
10. Hall, A. R., Dix, B. R., O'Carroll, S. J., and Braithwaite, A. W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med., 4: 1068-1072, 1998.
11. Turnell, A., Grand, R., and Gallimore, P. The replicative capacities of large E1B-null group A and C adenoviruses are independent of host cell p53 status. J. Virol., 73: 2074-2083, 1999.
12. Harada, J., and Berk, A. p53-independent, and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol., 73: 5333-5344, 1999.
13. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
14. Rogulski, K. R., Zhang, K., Kolozsvary, A., Kim, J. H., and Freytag, S. O. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin. Cancer Res., 3: 2081-2088, 1997.
15. Alfieri, A. A., and Hahn, E. W. An in situ method for estimating cell survival in a solid tumor. Cancer Res., 38: 3006-3011, 1978.
16. Hall, E. J. The physics and chemistry of radiation absorption. In: E. J. Hall (ed.), Radiobiology for the Radiobiologist, pp. 17-38. Philadelphia: Lipponcott Co., 1994.
17. Vollmer, C. M., Ribas, A., Butterfield, L. H., Dissette, V. B., Andrews, K. J., Eilber, F. C., Montejo, L. D., Chen, A. Y., Hu, B., Glaspy, J. A., McBride, W. H., and Economou, J. S. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. 59: 4369-4374, 1999.
18. Kirn, D., Ganley, I., Nemunaitis, J., Otto, R., Soutar, D., Kuhn, J., Heise, C., Propst, M., Maack, C., Eckhardt, G., Kaye, S., and Von Hoff, D. A. A Phase 1 clinical trial with ONYX-015 (a selectively replicating adenovirus) administered by intratumoral injection in patients with recurrent head and neck cancer. Cancer Gene Ther., 49 (Suppl.): S13, 1997.
19. Bergsland, E., Mani, S., Kirn, D., Fell, S., Heise, C., Maack, C., and Venook, A. Intratumoral injection of ONYX-015 for gastrointestinal tumors metastatic to the liver: a Phase 1 trial. Proc. Am. Soc. Clin. Oncol., 117: 211A, 1998.
20. Rogulski, K., Kim, J. H., Kim, S. H., and Freytag, S. Glioma cells transduced with an E. coli CD/HSV-I TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther., 8: 73-85, 1997.
21. Rogulski, K. R., Wing, M., Paielli, D. L., Gilbert, J. D., Kim, J. H., and Freytag, S. O. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther., 11: 67-76, 2000.